openPR Logo
Press release

Industry and Government Bodies Gather for Crucial Updates into Antibiotic Resistance in Just 3 Weeks at Superbugs USA 2016

10-26-2016 09:44 AM CET | Health & Medicine

Press release from: SMi Group

Superbugs & Superdrugs USA

Superbugs & Superdrugs USA

Just 3 weeks remain until SMi Group open its doors to host Superbugs & Superdrugs USA, the American installment of its long running European conference.

Following on from 18 years of expertise in pushing industry collaboration and knowledge to promote antibiotic drug discovery, the Superbugs & Superdrugs event will travel across the Atlantic for the first time to gather an audience of senior industry experts and leading government bodies to tackle the critical threat of antibiotic resistance.

Featured speakers include:

Dr Pilar Ramon-Pardo, Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO
Dr Christopher Houchens, Branch Chief, Antibacterials Program, BARDA
Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section, DMID, NIAID, NIH
Dr John Rex, Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca
Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research & Development LLC
Dr Mahesh Kumar, Vice President, Global Biological Research and Development, Zoetis
David Cook, Chief Scientific Officer , Blueberry Therapeutics Ltd

5 agenda highlights will consist of:

1 .HOST NATION KEYNOTES: The agenda will evaluate current progress in the development of the US National Action Plan through host nation keynotes presented by leading government bodies including PAHO/WHO, NIH and BARDA. Highlights include updates into PPP investment opportunities and results following the first of year of the US Government “CARB Initiative”.

Christopher Houchens, Branch Chief of BARDA’s Antibacterials Program, said:

"BARDA and its interagency partners, specifically the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID) in particular, have demonstrated success in providing direct support to developers of promising products capable of addressing the global threat of AMR that may have otherwise never been developed without support."

2. TALKS ON DRUG DISCOVERY: Attendees will be encouraged to develop clinical assets through strategic partnerships and will receive progressive insight on innovative developments in big pharma. Topics will include the discovery of new pathways, the microbial metagenomics approach, and zoonotic links between animals and humans to target emerging infectious diseases.

Dr Anthony Simon Lynch, Senior Scientific Director from Janssen Research & Development LLC commented:

"Sessions focused on novel platforms and agents in the treatment and prevention of diseases caused by so-called ‘Superbugs’ are all of interest as they cover a broad spectrum of alternate approaches and it’s always good to be cognizant of new science and potential opportunities."

Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines from Pfizer said:

"Pfizer believes that a mix of economic incentives, coupled with regulatory reforms specifically focused on antibiotics and vaccines for drug resistant strains and emerging infectious diseases, can successfully incentivize new R&D."

3. DIRECTION ON STRENGTHENING THE ANTIBIOTIC PIPELINE: The program will include presentations on restoring antibiotic sensitivity in multi-drug resistance infections with talks on targeting mechanisms, novel approaches in treating gram-negative infections, combination therapy, and protein based biologics as adjuncts to existing therapies.

David Cook, Chief Scientific Officer from Blueberry Therapeutics, singled out this session as being one of particular interest:

"I’m looking forward to the section on “Strengthening the Pipeline” and hearing about the other work going on in developing beta-lactamase inhibitors."

4. A LOOK AT ANIMAL MODELS: The first of two interactive workshops will be hosted by the UNT Health Science Centre and will offer in-depth discussions on animal models in antibiotic drug discovery. The session will cover topics on regulation, proof of concept studies and analyse supportive data.

5. REGULATORY GUIDANCE: The second workshop will determine PK/PD targets for optimising dosage requirements for new antibacterials with regulatory recommendations from the National Institute of Allergy & Infectious Diseases (NIAID) .

Further information including a detailed program and full speaker line-up is available online. Registration to attend can be made at superbugs-usa.com/openpr

A series of interviews with keynote speakers is also available to read in the event download centre at http://www.smi-online.co.uk/2016superbugsusa.asp#tab_downloads

Superbugs & Superdrugs USA 2016
Conference: Nov 14 – 15
Interactive workshops: Nov 16
Renaissance Woodbridge Hotel, Iselin, New Jersey

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.superbugs-usa.com/openpr or contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Rd, London SE1 7XW
Phone: 020 7827 6000
For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Industry and Government Bodies Gather for Crucial Updates into Antibiotic Resistance in Just 3 Weeks at Superbugs USA 2016 here

News-ID: 376400 • Views: 422

More Releases from SMi Group

Leonardo and SMi webinar invite to Adapting to the new normal - managing cyber r …
SMi Reports: A webinar on Adapting to the New Normal - Managing Cyber Risks to the Utilities Sector beyond COVID-19 will be hosted by Leonardo, taking place on 11 June 2020. Leonardo are hosting a free to attend webinar on Adapting to the New Normal - Managing Cyber Risks to the Utilities Sector beyond COVID-19. The one-hour webinar will focus on adapting to the new normal, by understanding and managing the
Just 1 Week to Go Until Future Armoured Vehicles Weapon Systems 2020
There is just 1 week left to go until Future Armoured Vehicles Weapon Systems 2020 will convene online to explore the next generation of fire superiority for armoured vehicles. This virtual conference will host senior military personnel and industry leaders from around the globe to explore the latest developments in firepower capabilities and weapon systems for next generation armoured vehicles. Industry experts will provide an overview of cutting-edge weaponry, ammunition systems
Envisagenics presents latest case study at Oligonucleotide Therapeutics and Deli …
SMi reports: Envisagenics will be presenting latest case study on RNA-therapeutics for Triple Negative Breast Cancer. Envisagenics is a spin out of the world-renowned Cold Spring Harbor Laboratory (CSHL) from the laboratory of Dr. Adrian R. Krainer, an expert in the field of splicing. The Krainer laboratory was the first to perform in-vitro splicing studies, identify the regulatory proteins of alternative splicing, discover the involvement of spliceosomal proteins in cancer and
Royal Navy Vice Admiral Jerry Kyd to Present Briefing at Defence Safety Conferen …
SMi Group's Defence Safety Conference will return to London for its third year on 5th - 6th October 2020. Supported by the UK MoD Defence Safety Authority for the third year in a row, the conference aims to build on last year's success, with representation from 10+ countries to explore the safe delivery of defence capabilities across the land, air and maritime domains, providing a holistic overview of safety within

All 5 Releases


More Releases for Superbugs

Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. For this reason, the Superbugs & Superdrugs conference, taking
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This
Kidney Infection Market | Superbugs | CAGR 5.2% | USA | PDF | PPT | Case Reports …
Kidney infection is a result of infection in the bladder that spreads to the kidney. Most common bacteria causing kidney infection is E. coli. Kidney infections are very common, especially, an aging population. The blood test is performed to make sure that the kidneys are functioning normally. The urine test, called a urinalysis, detects any abnormal cells or proteins that relate to a kidney problem. If the blood and urine
W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conf …
SMi Group reports: William J. Weiss - University of North Texas Health Science Center and Anthony Simon Lynch - Janssen supporting SMi's Superbugs & Superdrugs USA Conference, which is due to take place this November in New Jersey William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding,
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the
Superbugs: Exclusive Interviews Released with ABAC Therapeutics, Alchemy Biomedi …
SMI REPORTS: Expert insight into tackling the scientific, regulatory and economic challenges to combat antimicrobial resistance. It is imperative for medical experts and drug discovery specialists to stay on top of the latest clinical advancements, developments and industry initiatives related to antimicrobial resistance. For this reason, SMi Group have gathered industry experts and government bodies to share their insights at the 20th annual conference on Superbugs and Superdrugs taking place on